Popular brands on the market also include Ozempic’s sister drug Wegovy and Eli Lilly’s (LLY-0.02%) Zepbound. Soaring demand ...

Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

NEW YORK (Reuters) -U.S. healthcare spending rose by 7.5% to $4.9 trillion in 2023, driven by increased use of medical ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck & Co. has secured a licensing agreement with Chinese drugmaker Hansoh Pharma for an experimental oral weight-loss drug, ...

Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the ...

Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have ...

The European Union's drug regulator said it would review a potential link between Novo Nordisk's blockbuster diabetes drug, Ozempic, and a rare eye condition that causes vision loss after recent ...

The company behind KitKat has launched a protein drink that it claims suppresses appetite in the same way as popular ...

Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.